ZHANG Hao, ZHAO Pin, WU Zhi-ang. A Research on the Risk of Intervention in Antipyretics for Children[J]. Chinese Journal of Pharmacovigilance, 2012, 9(4): 218-221.
[1] 倪明.小儿解热镇痛药的不良反应与合理使用[J].中国医药指南,2011,09(1):65-67. [2] 兰玲.解热镇痛药不良反应 山西省6年共报告3 300余例[N].山西晚报,2011-01-07-(4). [3] 孙奕,巩桂双.七岁以内小儿感冒的发病监测[J].中国民政医学杂志,2002,14(4):213-214. [4] 张军.儿童感冒发病高峰提前[N].北京日报,2009-10-28-(6). [5] 雷波.合理选用小儿退热药[J].健康博览,2006.04.19-20. [6] 刘蕾,陈勇,白洁.儿童退热药物及合理选择[J].中国社区医师, 2010,12(30):25-26. [7] FDA .Best Pharmaceuticals for Children Act[EB/OL].http://www. fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugand- 8 CosmeticActFDCAct/default.htm. [8] FDA. Pediatric Research Equity Act[EB/OL].http://www.fda.gov/AboutFDA/WhatWeDo/History /Milestones/default.htm. [9] EMEA. Paediatric investigation plans[EB/OL].http://www.ema. europa.eu/ema/index.jsp curl=pages/regulation/document_listing/ 10 document_listing_000293.jsp&mid=WC0b01ac0580025b91& 11 jsenabled=true. [10] FDA. Recall: Children's and Infants' Tylenol Oral Suspension Products[EB/OL]. http://www.fda.gov/ForConsumers/ConsumerU pdates/ucm184092.htm. [11] FDA.Additions to the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Federal Register[EB/OL].[2000-01-04]http://www.fda.gov/ohrms/ dockets/98fr/100898b.txt.2000.1.4. [12] WHO. Consolidated List of Products-Pharmceuticals[EB/OL]. http://www.un.org/esa/coordination/CL12.pdf. [13] 张兰华,魏萍.我国儿科专用药注册现状分析及其对策[J].解放军药学,2011 27(2):178-180.